Exploring adjunctive therapies for cerebral malaria.
Front Cell Infect Microbiol
; 14: 1347486, 2024.
Article
en En
| MEDLINE
| ID: mdl-38410724
ABSTRACT
Cerebral malaria (CM) is one of the most severe complications of malaria infection characterized by coma and neurological effects. Despite standardized treatment of malaria infection with artemisinin-based combination therapies (ACT), the mortality rate is still high, and it primarily affects pediatric patients. ACT reduces parasitemia but fails to adequately target the pathogenic mechanisms underlying CM, including blood-brain-barrier (BBB) disruption, endothelial activation/dysfunction, and hyperinflammation. The need for adjunctive therapies to specifically treat this form of severe malaria is critical as hundreds of thousands of people continue to die each year from this disease. Here we present a summary of some potential promising therapeutic targets and treatments for CM, as well as some that have been tested and deemed ineffective or, in some cases, even deleterious. Further exploration into these therapeutic agents is warranted to assess the effectiveness of these potential treatments for CM patients.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
/
3_ND
/
4_TD
Problema de salud:
2_enfermedades_transmissibles
/
3_malaria
/
3_neglected_diseases
/
4_malaria
/
4_meningitis
Asunto principal:
Malaria Cerebral
Límite:
Child
/
Humans
Idioma:
En
Revista:
Front Cell Infect Microbiol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos